Zoetis

Health Care Pharmaceuticals Parsippany, New Jersey Last filing Feb 12, 2026 · FY2025

                    Revenue
                    FY2025
                
$9.5B
                    3y CAGR +5.4%
                    
                    P49
                    
                    n/a
                    
                    Net income
                    FY2025
                
$2.7B
                    Net margin +28.2%
                    
                    P90
                    
                    n/a
                    
                    Total assets
                    FY2025
                
$15.5B
                    ROA +17.3%
                    
                    P93
                    
                    n/a
                    
                    Operating cash flow
                    FY2025
                
$2.9B
                    FCF margin +24.1%
                    
                    P86
                    
                    n/a

15 yrs · FY2011–FY2025 9 filed · 0 derived · 0 blank

1Y 3Y 5Y 10Y

Dollars % of revenue % of assets YoY % CAGR

Each cell as a share of that year’s revenue.

Balance Sheet

Assets, liabilities, and equity

32 accounts · 1 year

Total assets $15.5B

Total liabilities $12.1B

Shareholders equity $3.3B

Account	2025	Trend
Assets
Cash and Cash Equivalents	24.4%
Accounts Receivable	16.8%
Inventory	25.7%
Prepaid Expenses	4.6%
Other Current Assets	4.6%
Total Current Assets	71.5%
Property,Plant and Equipment	38.9%
Operating Lease Assets	3.0%
Goodwill	29.2%
Intangible Assets	10.5%
Deferred Tax Assets	6.7%
Other Noncurrent Assets	3.5%
Total Assets	163.4%
Liabilities
Accounts Payable	5.1%
Accrued Liabilities	6.8%
Current Portion of Long Term Debt	0.0%
Other Current Liabilities	1.1%
Total Current Liabilities	23.6%
Long Term Debt	95.5%
Operating Lease Liabilities Noncurrent	2.1%
Deferred Tax Liabilities	1.5%
Other Noncurrent Liabilities	2.6%
Total Liabilities	128.2%
Equity
Preferred Stock	0.0%
Common Stock	0.1%
Additional Paid In Capital	11.6%
Retained Earnings	145.2%
Treasury Stock	112.9%
Accumulated Other Comprehensive Income	-8.8%
Noncontrolling Interest	0.0%
Total Stockholders Equity	35.2%
Total Liabilitiesand Equity	163.4%

Income Statement

Revenue, expense, and profitability

19 accounts · 1 year

Revenue $9.5B

Operating income $2.7B

Net income $2.7B

Account	2025	Trend
IncomeStatement
Revenues Total Revenue	100.0%
Expenses Cost of Revenue	28.2%
Expenses Research and Development	7.4%
Expenses Selling,General and Administrative	25.1%
Expenses Depreciation and Amortization	5.1%
Expenses Share Based Compensation	0.9%
Expenses Restructuring and Asset Impairment	0.5%
Expenses Operating Expenses	0.7%
Other Income Expense Operating Income	28.2%
Other Income Expense Interest Expense	2.3%
Other Income Expense Other Income/expense	-0.1%
Other Income Expense Income Before Tax	35.5%
Income Tax Income Tax Expense	7.3%
net Income net Income	28.2%
net Income Comprehensive Income	29.4%
Earnings Per Share Basic Eps	0.0%
Earnings Per Share Diluted Eps	0.0%
Earnings Per Share Weighted Average Shares Basic	4.7%
Earnings Per Share Weighted Average Shares Diluted	4.7%

Cash Flow Statement

Operating, investing, and financing flows

22 accounts · 1 year

Operating cash flow $2.9B

Investing cash flow $-748.0M

Financing cash flow $-1.9B

Account	2025	Trend
CashFlow
Operating Activities net Income	28.2%
Operating Activities Depreciation and Amortization	5.1%
Operating Activities Stock Based Compensation	0.9%
Operating Activities Deferred Income Taxes	-0.5%
Operating Activities Changes In Operating Assets and Liabilities	5.1%
Operating Activities Other Non Cash Items	0.9%
Operating Activities net Cash From Operating Activities	30.7%
Investing Activities Capital Expenditures	6.6%
Investing Activities Purchases of Investments	0.1%
Investing Activities Other Investing Activities	-0.0%
Investing Activities net Cash From Investing Activities	-7.9%
Financing Activities Proceeds From Debt	19.5%
Financing Activities Repayment of Debt	14.3%
Financing Activities Repurchase of Common Stock	34.2%
Financing Activities Dividends Paid	9.4%
Financing Activities Proceeds From Stock Issuance	0.1%
Financing Activities Other Financing Activities	-0.0%
Financing Activities net Cash From Financing Activities	-19.8%
Cash Reconciliation Effect of Exchange Rate On Cash	0.4%
Cash Reconciliation net Change In Cash	3.4%
Cash Reconciliation Cash At Beginning of Period	24.4%
Cash Reconciliation Cash At End of Period	24.4%

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 1 year

Ratio	2025
Profitability
Gross margin	+71.8%
Operating margin	+28.2%
Net margin	+28.2%
FCF margin	+24.1%
Growth
Revenue CAGR (3y)	+5.4%
Returns
ROE	+80.2%
ROA	+17.3%
ROIC	+21.1%
Liquidity
Current ratio	3.03x
Quick ratio	1.75x
Leverage
D/E	3.64x
Interest coverage	12.04x
Efficiency
Asset turnover	0.61x
Cash conversion cycle	+327d

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched

Zoetis

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Recent price history